Aclaris Therapeutics, Inc. (ACRS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.61-1.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ACRS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Prioritize a Phase 2b trial of ATI-052 in EoE after Phase 1b proof-of-concept results, consistent with the company’s stated development strategy and disciplined capital management.
Stated in 2 of the 2 supplied transcript quarters. Revenue was $1.629 million in 2026-Q2 and $1.777 million in 2025-Q2; the financials provide no clinical-program-specific revenue or trial outcome measure. Management reported positive Phase 1b results on October 27 and named EoE as the prioritized Phase 2b indication, showing clinical milestone delivery while the Phase 2b start remains planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Confirmed Intent to Initiate a Phase 2b Program Encompassing Asthma and AD with ATI-052 in the Fourth Quarter of 2026”
“Announced Phase 2b Program for ATI-052: ... initially targeting asthma, in the fourth quarter of 2026.”
Preserve the stated cash runway to support pipeline development through the end of 2028.
Stated in 2 of the 2 supplied transcript quarters. Cash, cash equivalents and marketable securities were $170.6 million at June 30, 2026, compared with $190.8 million at March 31, 2026; management repeated that funds are expected to cover operations through the end of 2028. The runway commitment persists, but the reported cash balance declined between these dates, so substantive delivery against the runway claim is limited in the supplied data.
“Strong Cash Runway Expected to Enable Development of Pipeline Through the End of 2028”
“Strong Cash Runway Expected to Enable Development of Pipeline Through 2028”
Pursue the planned Phase 2b lichen planus program for ATI-2138, including its planned study across lichen planus subtypes.
Stated in 2 of the 2 supplied transcript quarters. Revenue was $1.629 million in 2026-Q2 and $1.777 million in 2025-Q2; the supplied financials do not report ATI-2138-specific revenue or clinical outcomes. Management reaffirmed a fourth-quarter 2026 trial start, but the supplied disclosures show a planned milestone rather than a reported trial initiation, so delivery remains limited so far.
“Initiation of Phase 2b Clinical Program for Modzatinib (ATI-2138) ... Planned for the Fourth Quarter of 2026”
“Aclaris intends to initiate a phased Phase 2b basket study of ATI-2138 ... in the second half of 2026”
Report ATI-052 Phase 1b proof-of-concept results in atopic dermatitis and asthma and proceed with the planned Phase 2b development program.
Stated in 2 of the 2 supplied transcript quarters. Revenue was $1.629 million in 2026-Q2 and $1.777 million in 2025-Q2; the financials do not provide ATI-052-specific revenue. Management reported positive Phase 1b primary analysis results in both indications on October 27, completing the stated readout milestone; this is substantive clinical delivery, while subsequent Phase 2b progress remains planned.
“Reaffirmed Expectation of Top Line Results in the Second Half of 2026 from Two Ongoing Phase 1b POC Trials of ATI-052”
“Confirmed Expectation of Top Line Results in the Second Half of 2026 from Two Ongoing Phase 1b Proof-of-Concept (POC) Trials of ATI-052”
Complete the Phase 2 atopic dermatitis trial of bosakitug and report its top-line results as planned.
Stated in 2 of the 2 supplied transcript quarters. Revenue was $1.629 million in 2026-Q2 and $1.777 million in 2025-Q2; the supplied financials do not report bosakitug-specific revenue or trial results. Management reported completed enrollment and reaffirmed a fourth-quarter readout, but no bosakitug results appear in the supplied October 27 disclosure, so substantive delivery of the readout remains unverified.
“On Track for Expected Fourth Quarter 2026 Readout of Top Line Results from Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug”
“Completed Enrollment in Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug; Confirmed Expectation of Top Line Results in the Fourth Quarter of 2026”
Over the trailing year it converted 1.10x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
8 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.